Tags

New applications

Posted in September 12th, 2009
Published in Efficacy
Tags: PDE5, tadalafil

Recent data have indicated a potential association between epidemiological, physiologic, pathophysiologic, and treatment aspects of ED and lower urinary tract symptoms (LUTS) secondary to BPH. The 17.5 hour half-life of tadalafil makes it the most suitable PDE5 inhibitor for once-daily dosing in a trial of LUTS secondary to BPH. McVary and associates reported a multicentered, […]

read more from " New applications "

Safety and drug interactions

Posted in August 26th, 2009
Published in Pharmacology

As with every PDE5 inhibitor, tadalafil is absolutely contraindicated with nitrate medications for angina pectoris secondary to the potentiated hypotensive effect the drugs can have together. Because of the longer half-life, treatment with nitrate medications must be deferred for at least 48 hours after ingestion of tadalafil, compared with 24 hours for sildenafil (Viagra) and […]

read more from " Safety and drug interactions "

Duration of action

Posted in August 14th, 2009
Published in Pharmacology
Tags: ED, PDE5, tadalafil

Among the three PDE5 inhibitors, the half-life and thus duration of action is the pharmacologic parameter that is the most strikingly dissimilar. The half-life of tadalafil is 17.5 hours in normal healthy men and 21.6 hours in elderly men, while the half-lives of sildenafil and vardenafil are similar at 4 hours. This longer half-life provides […]

read more from " Duration of action "

Background on outcome measures

Posted in August 6th, 2009
Published in Efficacy
Tags: ED, IIEF, PDE5, SEP, tadalafil

Although the effectiveness of PDE5 inhibitors on such intermediate objective outcomes as penile rigidity through penile plethysmography with the RigiScan device (Dacomed Corporation, Minneapolis, MN, USA) has been studied, measuring the therapeutic effectiveness of tadalafil (Cialis Professional) is more accurately defined through an integration of the patient’s reported treatment response and tolerability with the reported […]

read more from " Background on outcome measures "